Goitrin ((S)-Goitrin), a product of glucosinolate-myrosinase reactions, is a potent inhibitor of thyroid peroxidase. Goitrin can inhibit iodine utilization by the thyroid. Goitrin also exhibits anti-influenza virus (H1N1) activity[1][2][3].
Laninamivir-d3 (R 125489-d3) is the deuterium labeled Laninamivir. Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively[1][2].
Triazavirin (Riamilovir sodium dihydrate) is a broad-spectrum antiviral agent targeting influenza viruses, lassa virus, TBEV and Ebola virus; suppresses the replication of influenza virus in cell culture and in chicken chorioallantoic membranes, and protects mice from death caused by type A and B influenza viruses.
Flutimide is a novel endonuclease inhibitor of influenza virus. Flutimide selectively inhibits endonuclease with an IC50 value of 3 μM. Flutimide shows antiviral activity in cell culture. Flutimide can be used for the research of acute contagious respiratory disease, such as influenza[1].
Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. (IC50 for canine influenza virus ranges from 0.17 to 0.21 μM).Target: OthersNitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. In vitro studies demonstrated much broader activity. Dr. Rossignol co-founded Romark Laboratories, with the goal of bringing nitazoxanide to market as an anti-parasitic drug. Initial studies in the USA were conducted in collaboration with Unimed Pharmaceuticals, Inc. (Marietta, GA) and focused on development of the drug for treatment of cryptosporidiosis in AIDS.The anti-protozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme dependent electron transfer reaction which is essential to anaerobic energy metabolism. It has also been shown to have activity against influenza A virus in vitro. The mechanism appears to be by selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to endoglycosidase H digestion. This impairs hemagglutinin intracellular trafficking and insertion of the protein into the host plasma membrane.
Neuraminidase-IN-2 is an anti-influenza compounds with IC50 values of 0.28, 0.27, 11.50, 0.089 and 23.44 µM for H1N1, 09H1N1, H3N2, H5N1 and H5N2, respectively. Neuraminidase-IN-2 has antiviral activity and low cytotoxicity[1].
Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor. Methyl brevifolincarboxylate exhibits inhibitory activity against influenza virus A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) with IC50s of 27.16 μM and 33.41 μM. Anti-oxidant activity[1][2].
Rimantadine (Flumadine) is an anti-influenza virus drug.Target: Influenza Virusrimantadine are oral antiviral drugs useful in the prophylaxis and treatment of influenza A virus infections. rimantadine has prophylactic efficacy comparable to amantadine but lower potential for causing adverse effects [1]. double-blind study of children with influenza-like illness. 37 received rimantadine for five days. Of the total 37 children in the rimantadine group, 27% were found to have resistant isolated compared with 6% in the total group receiving acetaminophen (P < .04). Furthermore, the mean inhibitory concentration of rimantadine increased with time in the rimantadine group (r = .4, P = .002) [2].
Neuraminidase-IN-9 (Compound 6l) is a potent influenza neuraminidase inhibitor with IC50 values of 0.12, 0.049 and 0.16 µM against H5N1, H5N2 and H5N6, respectively[1].
RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.
S119-8 is a broad spectrum inhibitor of influenza A and B viruses.
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1)[1].